PhD Supervisor, Chief Physician, MD, Postdoctoral Fellow, PhD/Master’s Supervisor, Deputy Director of Obstetrics and Gynecology at the First Affiliated Hospital of the University of Science and Technology of China, Director of the Western Gynecologic Oncology Department, National Natural Science Foundation Awardee. Published over 30 SCI papers with a highest impact factor of 15.302 and a cumulative impact factor exceeding 100. Authored over 10 papers in core Chinese journals. Led more than 10 projects, including the National Natural Science Foundation, USTC Talent Projects, China Postdoctoral Science Foundation Special and General Grants, Heilongjiang Postdoctoral Fund Special Grant, and Heilongjiang Natural Science Foundation, with total funding exceeding 2 million RMB. Research achievements have won six provincial awards, including the Heilongjiang Science and Technology Application Award. Serves as a young editorial board member for JCO, editorial board member for Modern Oncology, and reviewer for Chinese Journal of Clinical Obstetrics and Gynecology. Holds positions such as member of the Gynecologic Oncology Committee of the Chinese Anti-Cancer Association and young committee member of the Fifth Committee of the Chinese Medical Association Gynecologic Oncology Branch.
Contact Information
E-mail: xiabairong@ustc.edu.cn
Phone: 0551-65897880
Education and Work Experience
- 1996-2001: Bachelor’s Degree in Clinical Medicine, Mudanjiang Medical College
- 2009-2012: Master’s Degree in Obstetrics and Gynecology, Jiamusi University
- 2014-2017: PhD in Oncology, Harbin Medical University
- 2018-2020: Postdoctoral Fellow in Oncology, Harbin Medical University
- 2020-Present: Chief Physician (Department Head), Gynecologic Oncology, First Affiliated Hospital of USTC
- 2018-2020: Chief Physician, Department of Gynecology, Harbin Medical University Cancer Hospital
- 2012-2018: Associate Chief Physician, Department of Gynecology, Harbin Medical University Cancer Hospital
- 2003-2012: Attending Physician, Obstetrics and Gynecology, Second Hospital of Mingshui County, Heilongjiang
Academic Achievements and Impact
With over a decade dedicated to teaching and research in obstetrics and gynecology, supervised more than 10 PhD and Master’s students. Research achievements have been recognized with six provincial awards, including the Heilongjiang Science and Technology Application Award. Serves in editorial roles and as a reviewer for several journals, and holds committee positions in gynecologic oncology associations.
Published over 30 papers in SCI journals like Molecular Cancer, with a highest impact factor of 15.302, cumulative impact factor over 100, and approximately 200 citations.
Ongoing Projects (Principal Investigator Only)
| Project Name | Source | Funding ID | Total Funding (10,000 RMB) | Duration |
| Study on the Role and Mechanism of Long Non-Coding RNA-DANCR in Driving Platinum Resistance in Ovarian Cancer Cells | National Natural Science Foundation General Project | 57 | 2019-01 to 2022-12 |
| Research Start-up Fund, USTC Talent Project | 100 | 2020-07 to 2023-07 |
| Study on PARP Inhibitor Resistance Mechanism Using Ovarian Cancer Organoid Models | China Postdoctoral Science Foundation Special Grant | 18 | 2019-06 to 2021-06 |
| Study on Inhibiting Ovarian Cancer Peritoneal Metastasis by Engineering Exosomes to Interfere with DANCR | China Postdoctoral Science Foundation General Grant | 8 | 2019-09 to 2021-09 |
| Molecular Mechanism of lncRNA DANCR/miR-513a-5p/RAS-MAPK Pathway in Ovarian Cancer Chemotherapy Resistance | Heilongjiang Postdoctoral Fund Project | 7 | 2019-01 to 2021-01 |
Main Research Directions (Recruitment Specialties) and Content
Clinical Medicine
Obstetrics and Gynecology
1. Molecular mechanisms and targeted therapy research in gynecologic oncology
2. Research on the relationship between tumor microenvironment and treatment resistance
3. Comprehensive treatment and immunotherapy research in gynecologic oncology
Representative Papers (Last Five Years)
1. Chen Y, Lin H, Pi YN, Bairong Xia. Development and Validation of a Prognostic Signature Based on Immune Genes in Cervical Cancer. Front Oncol. 2021; 11:616530.
2. Pi YN#, Bairong Xia#, Jin MZ, Jin WL, Lou G. Exosomes: Powerful weapon for cancer nano-immunoengineering. Biochem Pharmacol. 2021; 186:114487.
3. Zhang Y#, Zhou H#, Zhang M, Bairong Xia, Lou G. Integrated analysis of a competing endogenous RNA network reveals an 11-lncRNA prognostic signature in ovarian cancer. Aging (Albany NY). 2020; 12(24):25153-25171.
4. Yang C#, Bairong Xia#, Zhang ZC, Zhang YJ, Lou G, Jin WL. Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant. Front Immunol. 2020; 11:577869.
5. Liu HD#, Bairong Xia#, Jin MZ, Lou G. Organoid of ovarian cancer: genomic analysis and drug screening. Clin Transl Oncol. 2020; 22(8):1240-1251.
6. Xie H#, Wang W#, Bairong Xia#, Jin W, Lou G. Therapeutic applications of PARP inhibitors in ovarian cancer. Biomed Pharmacother. 2020; 127:110204.
7. Chen Hong#, Bairong Xia#, Zheng Tongsen, Lou Ge. Immunoscore system combining CD8 and PD-1/PD-L1: A novel approach that predicts the clinical outcomes for cervical cancer. Int J Biol Markers. 2020; 35(1):65-73.
8. Yang C#, Bairong Xia#, Jin WL, Lou G. Circulating tumor cells in precision oncology: clinical applications in liquid biopsy and 3D organoid model. Cancer Cell Int. 2019; 19:341.
9. Jin SJ#, Jin MZ, Bairong Xia, Jin WL. Long Non-coding RNA DANCR as an Emerging Therapeutic Target in Human Cancers. Front Oncol. 2019; 9:1225.
10. Bairong Xia#,Mei Lin#,Wei Dong ,Hong Chen,Bing Li ,Xiaye Zhang ,Yan Hou ,Ge Lou, Upregulation of miR-874-3p and miR-874-5p inhibits epithelial ovarian cancer malignancy via SIK2, J Biochem Mol Toxicol 2018
11. Jin Ming-Zhu#, Xia Bai-Rong#, Xu Yu, Jin Wei-Lin. Curaxin CBL0137 Exerts Anticancer Activity via Diverse Mechanisms. Front Oncol. 2018 Dec 7; 8:598.
12. Lin M#, Bairong Xia#, Qin L, Chen H, Lou G. S100A7 Regulates Ovarian Cancer Cell Metastasis and Chemoresistance through MAPK Signaling and Is Targeted by miR-330-5p. DNA Cell Biol 2018; 37(5):491-500.
13. Bairong Xia#, Lin M#, Dong W, Chen H, Li B, Zhang X, Hou Y, Lou G. Upregulation of miR-874-3p and miR-874-5p inhibits epithelial ovarian cancer malignancy via SIK2. J Biochem Mol Toxicol. 2018; 32(8):e22168.
14. KaiYang#，BairongXia#，WenjieWang，JinlongCheng，MingzhuYin，HongyuX ie，Junnan Li，Libing Ma，ChunyanYang，Ang Li，Xin Fan，Harman S Dhillon，YanHou，Ge Lou，Kang Li()，A Comprehensive Analysis of Metabolomics andTranscriptomics in Cervical Cancer，Scientific Reports 2017
15. Bairong Xia#, Hou Y#, Chen H, Yang S, Liu T, Lin M, Lou G. Long non-coding RNA ZFAS1 interacts with miR-150-5p to regulate Sp1 expression and ovarian cancer cell malignancy. Oncotarget. 2017; 8(12):19534-19546.
16. Bairong Xia#, Li H#, Yang S, Liu T, Lou G. MiR-381 inhibits epithelial ovarian cancer malignancy via YY1 suppression. Tumor Biol. 2016; 37(7):9157-9167.
17. Chen, Hong#，Bairong Xia#，Liu, Tianbo，Lin, Mei，Lou, Ge，KIAA0101, a target gene of miR-429, enhances migration and chemoresistance of epithelial ovarian cancer cells.，Cancer Cell Int，2016.01.01，16：74~74
18. Bairong Xia#，Shanshan Yang，Tianbo Liu，Ge Lou，miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6，Molecular Cancer，2015.2.15，14（57）：1~13.
Laboratory Website
https://orcid.org/0000-0002-8782-1535